149 related articles for article (PubMed ID: 10494777)
1. Platelet compatibility of an artificial surface modified with functionally active heparin.
Mollnes TE; Videm V; Christiansen D; Bergseth G; Riesenfeld J; Hovig T
Thromb Haemost; 1999 Sep; 82(3):1132-6. PubMed ID: 10494777
[TBL] [Abstract][Full Text] [Related]
2. Effect of complement inhibition and heparin coating on artificial surface-induced leukocyte and platelet activation.
Lappegård KT; Fung M; Bergseth G; Riesenfeld J; Lambris JD; Videm V; Mollnes TE
Ann Thorac Surg; 2004 Mar; 77(3):932-41. PubMed ID: 14992902
[TBL] [Abstract][Full Text] [Related]
3. Discrimination between platelet-mediated and coagulation-mediated mechanisms in a model of complex thrombus formation in vivo.
Cadroy Y; Horbett TA; Hanson SR
J Lab Clin Med; 1989 Apr; 113(4):436-48. PubMed ID: 2522978
[TBL] [Abstract][Full Text] [Related]
4. Biocompatibility of extracorporeal circulation. In vitro comparison of heparin-coated and uncoated oxygenator circuits.
Videm V; Mollnes TE; Garred P; Svennevig JL
J Thorac Cardiovasc Surg; 1991 Apr; 101(4):654-60. PubMed ID: 2008104
[TBL] [Abstract][Full Text] [Related]
5. In vitro evaluation of new surface coatings for extracorporeal circulation.
Baksaas ST; Videm V; Fosse E; Karlsen H; Pedersen T; Mollnes TE; Hagve TA; Svennevig JL
Perfusion; 1999 Jan; 14(1):11-9. PubMed ID: 10074642
[TBL] [Abstract][Full Text] [Related]
6. The state of platelets preserved in extracorporeal circulation with a glycoprotein IIb/IIIa inhibitor.
Kondo N; Wakayama F; Suzuki Y; Fukui K; Takaya S; Fukuda I
Thromb Res; 2004; 113(5):303-10. PubMed ID: 15183042
[TBL] [Abstract][Full Text] [Related]
7. Physicochemical and blood compatibility characterization of polypyrrole surface functionalized with heparin.
Li Y; Neoh KG; Cen L; Kang ET
Biotechnol Bioeng; 2003 Nov; 84(3):305-13. PubMed ID: 12968284
[TBL] [Abstract][Full Text] [Related]
8. Silicon-carbide coated coronary stents have low platelet and leukocyte adhesion during platelet activation.
Monnink SH; van Boven AJ; Peels HO; Tigchelaar I; de Kam PJ; Crijns HJ; van Oeveren W
J Investig Med; 1999 Jul; 47(6):304-10. PubMed ID: 10431485
[TBL] [Abstract][Full Text] [Related]
9. Changes in platelet, granulocyte, and complement activation during cardiopulmonary bypass using heparin-coated equipment.
Fukutomi M; Kobayashi S; Niwaya K; Hamada Y; Kitamura S
Artif Organs; 1996 Jul; 20(7):767-76. PubMed ID: 8828766
[TBL] [Abstract][Full Text] [Related]
10. The influence of different heparin surface concentrations and antithrombin-binding capacity on inflammation and coagulation.
Johnell M; Larsson R; Siegbahn A
Biomaterials; 2005 May; 26(14):1731-9. PubMed ID: 15576147
[TBL] [Abstract][Full Text] [Related]
11. A new method for quantifying platelet deposition in flowing native blood in an ex vivo model of human thrombogenesis.
Bossavy JP; Sakariassen KS; Barret A; Boneu B; Cadroy Y
Thromb Haemost; 1998 Jan; 79(1):162-8. PubMed ID: 9459343
[TBL] [Abstract][Full Text] [Related]
12. Effects on blood compatibility in vitro by combining a direct P2Y12 receptor inhibitor and heparin coating of stents.
Christensen K; Larsson R; Emanuelsson H; Elgue G; Larsson A
Platelets; 2006 Aug; 17(5):318-27. PubMed ID: 16928604
[TBL] [Abstract][Full Text] [Related]
13. Comparison of three oxygenator-coated and one total-circuit-coated extracorporeal devices.
Baksaas ST; Videm V; Pedersen T; Karlsen H; Mollnes TE; Brosstad F; Svennevig JL
Perfusion; 1999 Mar; 14(2):119-27. PubMed ID: 10338323
[TBL] [Abstract][Full Text] [Related]
14. Artificial surface-induced cytokine synthesis: effect of heparin coating and complement inhibition.
Lappegård KT; Fung M; Bergseth G; Riesenfeld J; Mollnes TE
Ann Thorac Surg; 2004 Jul; 78(1):38-44; discussion 44-5. PubMed ID: 15223398
[TBL] [Abstract][Full Text] [Related]
15. Complement activation during extracorporeal circulation. In vitro comparison of Duraflo II heparin-coated and uncoated oxygenator circuits.
Svennevig JL; Geiran OR; Karlsen H; Pedersen T; Mollnes TE; Kongsgard U; Frøysaker T
J Thorac Cardiovasc Surg; 1993 Sep; 106(3):466-72. PubMed ID: 8361189
[TBL] [Abstract][Full Text] [Related]
16. Effect of heparin-PVA hydrogel on platelets in a chronic canine arterio-venous shunt.
Cholakis CH; Zingg W; Sefton MV
J Biomed Mater Res; 1989 Apr; 23(4):417-41. PubMed ID: 2708416
[TBL] [Abstract][Full Text] [Related]
17. Platelet activation after stenting with heparin-coated versus noncoated stents.
Gurbel PA; Bliden KP
Am Heart J; 2003 Oct; 146(4):E10. PubMed ID: 14564333
[TBL] [Abstract][Full Text] [Related]
18. Activation of blood platelets in chronic hepatitis and liver cirrhosis P-selectin expression on blood platelets and secretory activity of beta-thromboglobulin and platelet factor-4.
Panasiuk A; Prokopowicz D; Zak J; Matowicka-Karna J; Osada J; Wysocka J
Hepatogastroenterology; 2001; 48(39):818-22. PubMed ID: 11462931
[TBL] [Abstract][Full Text] [Related]
19. In vitro platelet interactions in whole human blood exposed to biomaterial surfaces: insights on blood compatibility.
Haycox CL; Ratner BD
J Biomed Mater Res; 1993 Sep; 27(9):1181-93. PubMed ID: 8126017
[TBL] [Abstract][Full Text] [Related]
20. In vitro platelet interactions with a heparin-polyvinyl alcohol hydrogel.
Cholakis CH; Sefton MV
J Biomed Mater Res; 1989 Apr; 23(4):399-415. PubMed ID: 2708415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
